Orphan Drug Approval May Mean New Treatment Option for Mesothelioma, According to Surviving Mesothelioma

Share Article

A company that produces a cancer vaccine called CRS-207 has been granted orphan drug status for the treatment of malignant mesothelioma, potentially opening new treatment possibilities for patients with this rare cancer.

Vaccine Granted Orphan Drug Status for Mesothelioma

New Orphan Drug Approved for Mesothelioma

The combination of CRS-207 together with chemotherapy may offer the promise of a potential new therapeutic regimen...

Patients with inoperable mesothelioma may soon have a new treatment option available to them, thanks to the FDA’s approval of CRS-207’s orphan drug application . Click here to read the full story on the Surviving Mesothelioma website.

CRS-207 is an immunotherapy vaccine made from a modified version of the bacteria that causes the food-borne illness Listeriosis. The FDA has agreed to give its manufacturer grant funding and other incentives to support continued testing and development of CRS-207 as a mesothelioma treatment.

“We believe the combination of CRS-207 together with chemotherapy may offer the promise of a potential new therapeutic regimen for patients suffering from mesothelioma,” says Dirk Brockstedt, PhD, Senior Vice President of Research and Development at Aduro.

News of the orphan drug approval was announced on the company website in mid-March. CRS-207 has already been granted orphan drug status for the treatment of pancreatic cancer.

“Orphan drugs hold particular significance for people with mesothelioma because the disease is both rare and currently incurable,” says Alex Strauss, Managing Editor at Surviving Mesothelioma. “Surviving Mesothelioma will continue to follow the progress of CRS-207 as it makes its way through the testing and approval process.”

To read more about how CRS-207 is thought to work against mesothelioma, see Mesothelioma Vaccine Receives Orphan Drug Approval, now available on the Surviving Mesothelioma website.

“Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma”, March 26, 2015, New Release, Aduro Biotech website, accessed March 30, 2015. http://www.aduro.com/view.cfm/121/press-release

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website